Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies.

[1]  Yi Yang,et al.  Phenotypic and functional characterization of cytokine-induced killer cells derived from preterm and term infant cord blood. , 2014, Oncology reports.

[2]  Feng Yan,et al.  Activation of T‐LAK‐cell‐originated protein kinase‐mediated antioxidation protects against focal cerebral ischemia–reperfusion injury , 2014, The FEBS journal.

[3]  Liping Wang,et al.  Pseudomonas aeruginosa injection enhanced antitumor cytotoxicity of cytokine-induced killer cells derived from cord blood. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  Jun Wu,et al.  Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors , 2014, Journal of Translational Medicine.

[5]  Jian-ying Zhang,et al.  Modification of chemokine receptor expression to enhance levels of trafficking receptors on autologous cytokine-induced killer cells derived from patients with colorectal cancer. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  E. Haddad,et al.  Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines. , 2014, Cytotherapy.

[7]  Pei Li,et al.  Efficacy of Erlotinib Plus Dendritic Cells and Cytokine-induced Killer Cells in Maintenance Therapy of Advanced Non–Small Cell Lung Cancer , 2014, Journal of immunotherapy.

[8]  Jian Jian Li,et al.  Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy with Cytokine-Induced Killer Cells Improves Survival in Gastric and Colorectal Cancer Patients , 2014, PloS one.

[9]  Y. Zeng,et al.  Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.

[10]  Ruhong Li,et al.  The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma , 2014, Tumor Biology.

[11]  X. Hao,et al.  Maintenance Therapy With Autologous Cytokine-induced Killer Cells in Patients With Advanced Epithelial Ovarian Cancer After First-line Treatment , 2014, Journal of immunotherapy.

[12]  B. Han,et al.  A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients , 2014, Tumor Biology.

[13]  C. Niu,et al.  Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression‐free survival for patients with hepatocellular carcinoma , 2014, International journal of cancer.

[14]  R. Sherkat,et al.  CD107a Expression and IFN-γ Production as Markers for Evaluation of Cytotoxic CD3+ CD8+ T Cell Response to CMV Antigen in Women with Recurrent Spontaneous Abortion , 2013, International journal of fertility & sterility.

[15]  S. Hongeng,et al.  Sunitinib Indirectly Enhanced Anti-Tumor Cytotoxicity of Cytokine-Induced Killer Cells and CD3+CD56+ Subset through the Co-Culturing Dendritic Cells , 2013, PloS one.

[16]  E. Haddad,et al.  Cord blood-derived and peripheral blood-derived cytokine-induced killer cells are sensitive to Fas-mediated apoptosis. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  Yanfang Jiang,et al.  Increased Numbers of NK Cells, NKT-Like Cells, and NK Inhibitory Receptors in Peripheral Blood of Patients with Chronic Obstructive Pulmonary Disease , 2013, Clinical & developmental immunology.

[18]  Haibo Zhang,et al.  Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer , 2013, Cancer Immunology, Immunotherapy.

[19]  C. Yee.  Adoptive T-Cell Therapy for Cancer: Boutique Therapy or Treatment Modality? , 2013, Clinical Cancer Research.

[20]  Seth M Steinberg,et al.  Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Y. Kaneda,et al.  Systemic Administration of a Novel Immune-Stimulatory Pseudovirion Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN-γ Production , 2012, Clinical Cancer Research.

[22]  J. Rossjohn,et al.  Recognition of CD1d-restricted antigens by natural killer T cells , 2012, Nature Reviews Immunology.

[23]  C. Klebanoff,et al.  Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy? , 2012, Journal of immunotherapy.

[24]  A. Jawad,et al.  Adoptive Transfer of Autologous T Cells Improves T-cell Repertoire Diversity and Long-term B-cell Function in Pediatric Patients with Neuroblastoma , 2012, Clinical Cancer Research.

[25]  E. Haddad,et al.  Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines. , 2012, Cytotherapy.

[26]  W. Piacibello,et al.  Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors , 2012, Expert opinion on biological therapy.

[27]  Hong-Xia Wang,et al.  Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety , 2012, Experimental Hematology & Oncology.

[28]  I. Schmidt-Wolf,et al.  New adoptive immunotherapy strategies for solid tumours with CIK cells , 2012, Expert opinion on biological therapy.

[29]  Hong-Xia Wang,et al.  Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. , 2012, Cytotherapy.

[30]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[31]  Yongmei Yin,et al.  The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study , 2012, Journal of Cancer Research and Clinical Oncology.

[32]  Sheng Wei,et al.  Randomized Study of Autologous Cytokine-Induced Killer Cell Immunotherapy in Metastatic Renal Carcinoma , 2012, Clinical Cancer Research.

[33]  A. Melcher,et al.  Immune activation by combination human lymphokine-activated killer and dendritic cell therapy , 2011, British Journal of Cancer.

[34]  Wenhua Zhu,et al.  Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. , 2011, International Immunopharmacology.

[35]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Yang Li,et al.  Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. , 2010, Anticancer research.

[37]  Jennifer A. Prescher,et al.  IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy , 2010, Cancer Immunology, Immunotherapy.

[38]  N. Xu,et al.  Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. , 2008, Anticancer research.

[39]  C. Schaar,et al.  Long‐term complete remission in IgD‐myeloma , 2006, European journal of haematology.

[40]  Jessica M Malenfant,et al.  CD107a as a functional marker for the identification of natural killer cell activity. , 2004, Journal of immunological methods.

[41]  G. Semenzato.  Lymphokine activated killer cells: a new approach to immunotherapy of cancer. , 1990, Leukemia.

[42]  Bin Zhang,et al.  Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood. , 2015, Cytotherapy.

[43]  Ataei Behrooz,et al.  CD107A EXPRESSION AND IFN-γ PRODUCTION AS MARKERS FOR EVALUATION OF CYTOTOXIC CD3+ CD8+CYTOTOXIC T LYMPHOCYTE, CMV, RECURRENT ABORTION T CELL RESPONSE TO CMV ANTIGEN IN WOMEN WITH RECURRENT SPONTANEOUS ABORTION , 2014 .

[44]  Y. Shao,et al.  Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. , 2011, Clinical immunology.

[45]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.